department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Eikon Therapeutics, Inc. ($EIKN) · pharmadog

PUBLIC COMPANY

$EIKNEikon Therapeutics, Inc.

Millbrae, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Phase 2

Fallopian Tube Cancer

resiquimod sulfate

Squamous Non-Small Cell Lung Cancer

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

21 open roles at Eikon Therapeutics, Inc. →

Where Eikon Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 6

departmentClinical 5 People & Talent 5 R&D / Discovery 3 Biostatistics / Data 2 Finance 2 IT & Engineering 2

News

no news has mentioned this company yet

identifiers

ticker

$EIKN

SEC CIK

0001861123

country

US

source

sec_tickers

top tags

Oncology2 NSCLC1

mentioned in

0news items

entity-linker matched

$EIKN

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 11m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase2A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumorsrecruitingn=156
phase2EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumorsrecruitingn=160
phase3A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.not yet recruitingn=750
phase1Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumorscompletedn=1
phase3Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.recruitingn=740
phase2A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCrecruitingn=70
phase1BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumabcompletedn=40
phase2BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumorscompletedn=1

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 6, 26BUYColumn Group IV GP, LP· 10% owner1,437,323 sh @ $18.00$25.87M↗
Feb 6, 26BUYColumn Group IV GP, LP· 10% owner630,881 sh @ $18.00$11.36M↗
Feb 6, 26BUYColumn Group IV GP, LP· 10% owner49,556 sh @ $18.00$892K↗
Feb 4, 26BUYWolfe Josh· 10% owner138,888 sh @ $18.00$2.50M↗
Feb 4, 26BUYLux Venture Partners V, LLC· 10% owner138,888 sh @ $18.00$2.50M↗
Feb 4, 26BUYWolfe Josh· 10% owner138,888 sh @ $18.00$2.50M↗
Feb 4, 26BUYLux Venture Partners V, LLC· 10% owner138,888 sh @ $18.00$2.50M↗
Feb 4, 26BUYFRAZIER KENNETH C· director111,111 sh @ $18.00$2.00M↗
Feb 4, 26BUYForesite Capital Management IV, LLC· 55,555 sh @ $18.00$1000K↗

routine RSU / option mechanics (6)

Mar 2, 26grantBowie Alfred Lloyd Jr. · Chief Financial Officer67,044 sh
Mar 2, 26grantFRAZIER KENNETH C · director25,873 sh
Mar 2, 26grantBaynes Roy D. · Chief Medical Officer134,088 sh
Mar 2, 26grantThorner Benjamin Bruno · See Remarks67,044 sh
Mar 2, 26grantHuffines Robert Luther · director25,873 sh

Mar 2, 26

grant

Klobuchar Michael A · Chief Operating Officer

87,157 sh